Related Experiment Video
Updated: May 30, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer
1Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, L'Hospitalet, Barcelona, Spain.
Abstract:
MicroRNAs (miRNAs) are recognized as being central players in many biological processes and cellular pathways. Their roles in disease have been highlighted first by observation of their aberrant expression profiles in human tumors, and then by in vitro and in vivo functional studies in transformed cells and model organisms. One of the most commonly observed features of miRNAs in malignancies is a defect in their production. Although several causes may be associated with this phenomenon, such as upstream oncogenic/tumor-suppressor defects and alterations in the miRNA-processing machinery, epigenetic inactivation is the prime suspect. The number of miRNAs with putative growth-inhibitory functions undergoing promoter CpG island hypermethylation in human cancer is growing fast and more detailed biological studies are necessary. The recognition of miR-124a and miR-34b/c as bona fide tumor-suppressor miRNAs undergoing DNA methylation-associated silencing in a wide spectrum of human neoplasms is a good starting point to be followed by other candidate miRNAs. Most importantly, even at this early stage, the transcriptional repression of miRNAs by hypermethylation of their corresponding promoter loci seems to be a common feature of all human tumors. This will have translational consequences for the management of the disease.
Insights
Epigenetic silencing of microRNAs (miRNAs) through promoter hypermethylation is a common event in human cancers, impacting tumor suppressor functions and disease management.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- MicroRNAs (miRNAs) are crucial regulators of biological processes and cellular pathways.
- Aberrant miRNA expression is observed in human tumors, suggesting roles in disease pathogenesis.
- Defects in miRNA production, particularly epigenetic inactivation, are common in malignancies.
Purpose of the Study:
- To investigate the role of epigenetic silencing in miRNA dysregulation in cancer.
- To identify specific tumor-suppressor miRNAs affected by DNA methylation.
- To establish the prevalence of miRNA promoter hypermethylation in human neoplasms.
Main Methods:
- Analysis of miRNA expression profiles in human tumors.
- Functional studies in vitro and in vivo.
- Investigation of promoter CpG island methylation status for candidate miRNAs.
- Assessment of DNA methylation-associated silencing mechanisms.
Main Results:
- Epigenetic inactivation, specifically promoter CpG island hypermethylation, is a primary cause of miRNA production defects in cancer.
- Tumor-suppressor miRNAs, such as miR-124a and miR-34b/c, undergo DNA methylation-associated silencing in various human neoplasms.
- Transcriptional repression of miRNAs via promoter hypermethylation is a frequent hallmark across human tumors.
Conclusions:
- Epigenetic silencing of miRNAs is a common mechanism contributing to tumorigenesis.
- Understanding miRNA methylation is crucial for developing novel cancer therapies.
- The findings have significant translational implications for cancer management and treatment strategies.
Related Concept Videos
MicroRNAs
MicroRNAs
MicroRNAs
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Abnormal Proliferation

